BION - BB Biotech AG
SIX
->
Healthcare
->
Biotechnology
Kusnacht,
Switzerland
Type: Equity
BION price evolution
BION
| (in millions $) | 29 Jun 2021 | 30 Mar 2021 | 30 Dec 2020 | 29 Sep 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.03 | $1.03 | $2.29 | $2.29 |
| Short term investments | ||||
| Net receivables | $14.17 | $14.17 | $19.34 | $19.34 |
| Inventory | ||||
| Total current assets | $15.2 | $15.2 | $21.62 | $21.62 |
| Long term investments | ||||
| Property, plant & equipment | $96.63 | $96.63 | $93.54 | $93.54 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $112.53 | $112.53 | $115.88 | $115.88 |
| Current liabilities | ||||
| Accounts payable | $94.96 | $94.96 | $89.04 | $89.04 |
| Deferred revenue | ||||
| Short long term debt | $2.59 | $2.59 | $2.59 | $2.59 |
| Total current liabilities | $119.36 | $119.36 | $112.76 | $112.76 |
| Long term debt | $56.69 | $56.69 | $59.02 | $59.02 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $183.7 | $183.7 | $177.58 | $177.58 |
| Shareholders' equity | ||||
| Retained earnings | -$134.08 | -$134.08 | -$124.69 | -$124.69 |
| Other shareholder equity | -$6.69 | -$6.69 | -$6.61 | -$6.61 |
| Total shareholder equity | -$71.32 | -$71.32 | -$61.84 | -$61.84 |
| (in millions $) | 29 Apr 2022 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.01 | $2.29 | $0.08 | $0.47 |
| Short term investments | ||||
| Net receivables | $5.47 | $19.34 | $77.11 | $56.81 |
| Inventory | ||||
| Total current assets | $5.48 | $21.62 | $77.2 | $57.28 |
| Long term investments | ||||
| Property, plant & equipment | $93.54 | $49.54 | $41.64 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $5.48 | $115.88 | $127.52 | $99.75 |
| Current liabilities | ||||
| Accounts payable | $89.04 | $35.78 | $13.8 | |
| Deferred revenue | ||||
| Short long term debt | $2.59 | $5.76 | $7.69 | |
| Total current liabilities | $3.12 | $112.76 | $69.91 | $40.17 |
| Long term debt | $0.78 | $59.02 | $1.01 | $7.86 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $3.9 | $177.58 | $77.46 | $48.53 |
| Shareholders' equity | ||||
| Retained earnings | -$73.12 | -$124.69 | -$4.45 | -$3.35 |
| Other shareholder equity | -$0.23 | -$6.61 | -$6.71 | -$6.53 |
| Total shareholder equity | $1.58 | -$61.84 | $49.89 | $51.17 |
| (in millions $) | 29 Jun 2021 | 30 Mar 2021 | 30 Dec 2020 | 29 Sep 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.28 | $0.28 | $38.23 | $38.23 |
| Cost of revenue | $2.08 | $2.08 | $35.46 | $35.46 |
| Gross Profit | -$1.8 | -$1.8 | $2.77 | $2.77 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $2.53 | $2.53 | $64.06 | $64.06 |
| Total operating expenses | $4.6 | $4.6 | $98.76 | $98.76 |
| Operating income | -$4.32 | -$4.32 | -$60.53 | -$60.53 |
| Income from continuing operations | ||||
| EBIT | -$4.32 | -$4.32 | -$60.53 | -$60.53 |
| Income tax expense | $0.66 | $0.66 | ||
| Interest expense | -$1.12 | -$1.12 | -$1.09 | -$1.09 |
| Net income | ||||
| Net income | -$4.7 | -$4.7 | -$59.43 | -$59.43 |
| Income (for common shares) | -$4.7 | -$4.7 | -$59.43 | -$59.43 |
| (in millions $) | 29 Apr 2022 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.2 | $103.67 | $24.06 | $1.54 |
| Cost of revenue | $5.85 | $97.41 | $21.01 | $3.01 |
| Gross Profit | -$4.65 | $6.26 | $3.05 | -$1.47 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $61.45 | $132.2 | $8.84 | $7.94 |
| Total operating expenses | $65.23 | $228.01 | $29.84 | $10.94 |
| Operating income | -$64.03 | -$124.34 | -$5.77 | -$9.4 |
| Income from continuing operations | ||||
| EBIT | -$64.03 | -$124.34 | -$5.77 | -$9.4 |
| Income tax expense | $1.31 | $1.18 | $0.01 | |
| Interest expense | -$2.92 | -$2.78 | -$1.8 | -$1.57 |
| Net income | ||||
| Net income | -$64.51 | -$121.55 | -$0.19 | -$10.93 |
| Income (for common shares) | -$64.51 | -$121.55 | -$0.19 | -$10.93 |
| (in millions $) | 29 Jun 2021 | 30 Mar 2021 | 30 Dec 2020 | 29 Sep 2020 |
|---|---|---|---|---|
| Net income | -$4.7 | -$4.7 | -$59.43 | -$59.43 |
| Operating activities | ||||
| Depreciation | $1.15 | $1.15 | $0.69 | $0.69 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $2.24 | $2.24 | -$2.47 | -$2.47 |
| Investing activities | ||||
| Capital expenditures | -$2.57 | -$2.57 | -$17.63 | -$17.63 |
| Investments | ||||
| Total cash flows from investing | -$2.57 | -$2.57 | -$17.67 | -$17.67 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$0.26 | -$0.26 | $21.19 | $21.19 |
| Total cash flows from financing | -$0.26 | -$0.26 | $21.19 | $21.19 |
| Effect of exchange rate | -$0.04 | -$0.04 | -$0.06 | -$0.06 |
| Change in cash and equivalents | -$0.63 | -$0.63 | $0.98 | $0.98 |
| (in millions $) | 29 Apr 2022 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Net income | -$64.51 | -$121.55 | -$0.19 | -$10.93 |
| Operating activities | ||||
| Depreciation | $3.5 | $2.77 | $2.8 | $1.38 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $41.84 | -$12.9 | $0.38 | -$9.67 |
| Investing activities | ||||
| Capital expenditures | -$4.56 | -$36.44 | -$5.43 | -$5.4 |
| Investments | ||||
| Total cash flows from investing | -$4.56 | -$36.4 | -$5.43 | -$5.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$44.86 | $51.41 | $4.85 | $1.37 |
| Total cash flows from financing | -$40.76 | $51.41 | $4.85 | $15.05 |
| Effect of exchange rate | $1.76 | $0.1 | -$0.18 | $0.31 |
| Change in cash and equivalents | -$1.71 | $2.21 | -$0.39 | $0.3 |
News
|
After layoffs, Molecular Templates overhauls C-suite
American City Business Journals
4 Aug 2023
|
|
3 Stocks Insiders Are Buying
Benzinga via Yahoo Finance
22 Sep 2021
|
|
3 Stocks Insiders Are Buying
Benzinga via Yahoo Finance
12 Sep 2021
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $77.01M |
|---|---|
| EBITDA | -$126.02M |
| EBIT | -$129.70M |
| Net Income | -$128.25M |
| Revenue Q/Q | -97.97% |
| Revenue Y/Y | 56.00% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -112.30% |
| ROE | 192.63% |
| Debt/Equity | 2.47 |
|---|---|
| Net debt/EBITDA | -1.45 |
| Current ratio | 0.13 |
| Quick ratio | N/A |